In contrast, a beneficial impact of SSRIs on neurogenesis and pathologic biomarkers, including amyloid burden and tau deposits, has been reported [4, 5], along with evidence suggesting they may delay the progression from mild cognitive impairment (MCI) to Alzheimer’s dementia (AD) [6, 7] among persons with depression. The gene discussed is MAPT; the disease is Alzheimer disease.